Diabetes Care, 41
Recent research has also associated long-term GLP-1 drug use with an increased risk of vision problems
KPV is taken up directly via PepT1 in the small intestine and colon
Acting as incretin mimetics, they enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety, addressing several core abnormalities in T2DM pathophysiology ( Since the approval of exenatide in 2005, the GLP-1 RA class has expanded to include liraglutide, semaglutide, dulaglutide, and lixisenatide, each differing in half-life, route of administration, and molecular structure ( Pancreatic cancer has drawn particular scrutiny due to its high fatality rate and some early observational reports suggesting elevated risk with incretin-based therapies ( Given the expanding use of GLP-1 RAs in populations already at elevated risk for gastrointestinal malignancies, there is a clear need for a comprehensive synthesis of high-quality evidence ( 2 Materials and methods 2.1 Search strategy and data sources The systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines (Supplementary Table S1
Tirzepatide (Zepbound) FDA-indicated for obesity and sleep apnea A dual GLP-1/GIP receptor agonist
